Brief: Corvus Pharmaceuticals Announces Orphan Drug Designation Granted To Soquelitinib For The Treatment Of T Cell Lymphoma
08/02/2024 22:28
Feb 8 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
TO SOQUELITINIB FOR THE TREATMENT OF T CELL LYMPHOMA
* CORVUS : SOQUELITINIB EXPECTED TO ADVANCE INTO PHASE 3
REGISTRATIONAL CLINICAL TRIAL IN PATIENTS WITH RELAPSED
PERIPHERAL T CELL LYMPHOMA IN Q2 2024
Source text for Eikon: ID:nGNX35n0XJ
Further company coverage: CRVS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental